| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 159, Issue 2 650-663, Copyright © 1997 by American Association of Immunologists
ARTICLES |
RM Kedl and MF Mescher
The Center for Immunology and the Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis 55455, USA.
The response of CD8+ T cells to allogeneic tumor was studied by adoptive transfer of cells from TCR transgenic 2C mice specific for Ld alloantigen. Transferred cells were monitored during the course of a response to i.p. challenge with live P815 (H-2d) using the 1B2 mAb specific for the 2C TCR. Tumor was present in the draining LN and spleen within 3 to 4 days of challenge. The first changes in 1B2+ cells occurred in the spleen on day 4; VLA-4 expression increased in an Ag- specific manner and L-selectin expression decreased in an Ag- nonspecific manner. The number of 1B2+ cells in the spleen declined over days 4 to 6. The first detectable increase in CD25 expression and blast transformation was in the peritoneal cavity beginning days 5 and 6. Clonal expansion was largely limited to this site and was maximal on day 8. As expansion occurred in the peritoneal cavity; the number of 1B2+ cells in the draining LN and spleen also increased. These cells had an activated phenotype (CD44(high), VLA-4(high)) but most did not express CD25 and were not blasts. These results suggest that initial Ag recognition in the spleen results in altered expression of adhesion receptors so that cells gain access to the peritoneal cavity where they undergo clonal expansion and differentiation. Following the response, 1B2+ cells decline in number but a memory population (CD44(high), L- selectin(high and low)) persists for long times in the spleen and LN.
This article has been cited by other articles:
|
|
 |
|
  T. F. Gajewski Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment Clin. Cancer Res., September 15, 2007; 13(18): 5256 - 5261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Ryan and T. D. Schell Accumulation of CD8+ T Cells in Advanced-Stage Tumors and Delay of Disease Progression following Secondary Immunization against an Immunorecessive Epitope J. Immunol., July 1, 2006; 177(1): 255 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Benigni, V. S. Zimmermann, S. Hugues, S. Caserta, V. Basso, L. Rivino, E. Ingulli, L. Malherbe, N. Glaichenhaus, and A. Mondino Phenotype and Homing of CD4 Tumor-Specific T Cells Is Modulated by Tumor Bulk J. Immunol., July 15, 2005; 175(2): 739 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Wang, R. Yuan, Y. Feng, R. El-Asady, D. L. Farber, R. E. Gress, P. J. Lucas, and G. A. Hadley Regulation of CD103 Expression by CD8+ T Cells Responding to Renal Allografts J. Immunol., January 1, 2004; 172(1): 214 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Richards, S. L. Dalheimer, M. I. Hertz, and D. L. Mueller Trachea Allograft Class I Molecules Directly Activate and Retain CD8+ T Cells That Cause Obliterative Airways Disease J. Immunol., December 15, 2003; 171(12): 6919 - 6928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Yu, M. T. Spiotto, Y. Lee, H. Schreiber, and Y.-X. Fu Complementary Role of CD4+ T Cells and Secondary Lymphoid Tissues for Cross-presentation of Tumor Antigen to CD8+ T Cells J. Exp. Med., April 21, 2003; 197(8): 985 - 995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Gu, A. Laouar, J. Wan, M. Daheshia, J. Lieberman, W. M. Yokoyama, H. R. Katz, and N. Manjunath The gp49B1 Inhibitory Receptor Regulates the IFN-{gamma} Responses of T Cells and NK Cells J. Immunol., April 15, 2003; 170(8): 4095 - 4101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. E. Harmala, E. G. Ingulli, J. M. Curtsinger, M. M. Lucido, C. S. Schmidt, B. J. Weigel, B. R. Blazar, M. F. Mescher, and C. A. Pennell The Adjuvant Effects of Mycobacterium tuberculosis Heat Shock Protein 70 Result from the Rapid and Prolonged Activation of Antigen-Specific CD8+ T Cells In Vivo J. Immunol., November 15, 2002; 169(10): 5622 - 5629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Schmidt and M. F. Mescher Peptide Antigen Priming of Naive, But Not Memory, CD8 T Cells Requires a Third Signal That Can Be Provided by IL-12 J. Immunol., June 1, 2002; 168(11): 5521 - 5529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Tham, P. Shrikant, and M. F. Mescher Activation-Induced Nonresponsiveness: A Th-Dependent Regulatory Checkpoint in the CTL Response J. Immunol., February 1, 2002; 168(3): 1190 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Kedl, M. Jordan, T. Potter, J. Kappler, P. Marrack, and S. Dow CD40 stimulation accelerates deletion of tumor-specific CD8+ T cells in the absence of tumor-antigen vaccination PNAS, August 23, 2001; (2001) 191371898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Finke, F. Baribaud, H. Diggelmann, and H. Acha-Orbea Extrafollicular Plasmablast B Cells Play a Key Role in Carrying Retroviral Infection to Peripheral Organs J. Immunol., May 15, 2001; 166(10): 6266 - 6275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Skinner, M. A. Daniels, C. S. Schmidt, S. C. Jameson, and A. T. Haase Cutting Edge: In Situ Tetramer Staining of Antigen-Specific T Cells in Tissues J. Immunol., July 15, 2000; 165(2): 613 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Manjunath, P. Shankar, B. Stockton, P. D. Dubey, J. Lieberman, and U. H. von Andrian A transgenic mouse model to analyze CD8+ effector T cell differentiation in vivo PNAS, November 23, 1999; 96(24): 13932 - 13937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ohashi, S. Iwata, K. Kamiguchi, and C. Morimoto Tyrosine Phosphorylation of Crk-Associated Substrate Lymphocyte-Type Is a Critical Element in TCR- and {beta}1 Integrin-Induced T Lymphocyte Migration J. Immunol., October 1, 1999; 163(7): 3727 - 3734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Schmidt and M. F. Mescher Adjuvant Effect of IL-12: Conversion of Peptide Antigen Administration from Tolerizing to Immunizing for CD8+ T Cells In Vivo J. Immunol., September 1, 1999; 163(5): 2561 - 2567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Deeths, R. M. Kedl, and M. F. Mescher CD8+ T Cells Become Nonresponsive (Anergic) Following Activation in the Presence of Costimulation J. Immunol., July 1, 1999; 163(1): 102 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Curtsinger, C. S. Schmidt, A. Mondino, D. C. Lins, R. M. Kedl, M. K. Jenkins, and M. F. Mescher Inflammatory Cytokines Provide a Third Signal for Activation of Naive CD4+ and CD8+ T Cells J. Immunol., March 15, 1999; 162(6): 3256 - 3262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Shrikant and M. F. Mescher Control of Syngeneic Tumor Growth by Activation of CD8+ T Cells: Efficacy Is Limited by Migration Away from the Site and Induction of Nonresponsiveness J. Immunol., March 1, 1999; 162(5): 2858 - 2866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Kedl and M. F. Mescher Qualitative Differences Between Naive and Memory T Cells Make a Major Contribution to the More Rapid and Efficient Memory CD8+ T Cell Response J. Immunol., July 15, 1998; 161(2): 674 - 683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Curtsinger, D. C. Lins, and M. F. Mescher CD8+ Memory T Cells (CD44high, Ly-6C+) Are More Sensitive than Naive Cells (CD44low, Ly-6C-) to TCR/CD8 Signaling in Response to Antigen J. Immunol., April 1, 1998; 160(7): 3236 - 3243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Kedl, M. Jordan, T. Potter, J. Kappler, P. Marrack, and S. Dow CD40 stimulation accelerates deletion of tumor-specific CD8+ T cells in the absence of tumor-antigen vaccination PNAS, September 11, 2001; 98(19): 10811 - 10816. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
